Global Pulmonary Edema Market Size, Share, Forecast Report, 2020-2027

Pulmonary edema or lung congestion is a medical condition characterized by the presence of excessive fluid in the lungs. This may interfere with the exchange of gases leading to respiratory failures. Many cardiac and non-cardiac conditions are associated with the disease which occurs when the heart is unable to meet the body demands. This can be exampled by congestive heart failure. Dyspnea, palpitations, fatigue, wheezing, and others are some of the common symptoms of pulmonary edema. The treatment procedures for the disease vary with cause. However, supplemental oxygen and medications mount the backgrounds for a majority of the treatment methods. Increasing prevalence of pulmonary edema and diseases like kidney failure, heart diseases, pancreatitis is estimated to be the major driver for the market growth during the forecast period. According to the National Kidney Foundation in 2015, about 10% of the world’s total population is estimated to be affected by chronic kidney diseases (CKD). Moreover, it is estimated that millions of patients diagnosed with the disease die every year due to unaffordability for treatment. Additionally, growing geriatric population boosts the market growth. However, low per capita healthcare expenditure in the middle and low-income countries followed by the lack of awareness is projected to restrain the market growth.

The global pulmonary edema market is expected to grow at a CAGR of ~7.2% during the forecast period.
Segmentation

The global pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is segmented into cardiogenic edema, cardiogenic edema, and others.

On the basis of the diagnosis, the market is categorized into blood tests, imaging, and others. The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others. The imaging segment is sub-segmented into chest x-ray, electrocardiogram, echocardiogram, transesophageal echocardiography, pulse oximetry, and others. On the basis of the treatment, the market is segmented into preload reducers, morphine, suction catheter, and others. The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others. On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.
Some of the key players in the global Pulmonary Edema Market

Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan).